Home
Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. Market Share Analysis for July 2026

this domain may be for sale!

Industry: N/A

Domainnivalis.com

Year Founded2008

Employees51 - 200

Annual Revenue< $1M

Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (including company regionals)

nivalis.com

See more website traffic and engagement information

Total visits to Nivalis Therapeutics, Inc.'s top domains

Understand Nivalis Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Nivalis Therapeutics, Inc.'s top domains

Analyze Nivalis Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Nivalis Therapeutics, Inc.'s top domains

See how Nivalis Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Nivalis Therapeutics, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Nivalis Therapeutics, Inc.

These are the website technologies, by industry, used by Nivalis Therapeutics, Inc. top domains

Advertising (3)

Google Adsense

Domain Parking (2)

Parking Crew

Payment & Currencies (2)

Pound Sterling

Content Management System (1)

Kentico

More Technologies

5

See all

News & Signals from Nivalis Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCarruthers leaves Nivalis Therapeutics, Inc. as Interim President, Chief Financial Officer and Secretary.Mr. Carruthers joins OnKure from Nivalis Therapeutics (Nasdaq: NVLS), where he served as Interim President, Chief Financial Officer and Secretary.

NewsAlpine Immune Sciences Inc. merged with Nivalis Therapeutics, Inc. on Jan 1st '17.Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading company focused on the development of proprietary, protein-based immunotherapies to modulate the immune system, today announced the closing of its previously disclosed merger with Nivalis Therapeutics (NASDAQ: NVLS), effective July 24, 2017.